No | Gender | Age (year) | Duration (month) | DAS28 at baseline | CRP (mg/dl) | RF (IU/ml) | ANA (×) | MMP-3 (ng/ml) | HAQ-DI | Clinical manifestation | Time of infusion reaction (weeks) | MTX (mg/week) | PRED (mg/day) | Adherence to infliximab |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | F | 51 | 60 | 6.9 | 7.8 | 12 | 160 | 346 | 2.6 | Chills, fever, dyspnoea | 38 | 13 | 0 | Discontinue |
2 | F | 52 | 9 | 6.6 | 6.9 | 444 | 0 | 188 | 2.1 | Hot flushes, headache, subfever | 1 | 8 | 10 | Continue |
3 | M | 69 | 624 | 5.7 | 3.9 | 191 | 80 | 180 | 1.8 | Anaphylactoid reaction, hypotension | 2 (after 3-year interval) | 6 | 5 | Discontinue |
4 | F | 40 | 50 | 4.8 | 2.9 | 864 | 80 | 200 | 1.3 | Urticaria | 14 | 12.5 | 0 | Discontinue |
5 | F | 50 | 97 | 3.5 | 0.3 | 23 | 80 | 121 | 0.3 | Urticaria | 30 | 10.5 | 5 | Discontinue |
6 | F | 68 | 48 | 4.5 | 3.2 | 42 | 80 | 95 | 0.13 | Erythema | 14 | 8 | 0 | Discontinue |
7 | M | 65 | 240 | 4.8 | 2.8 | 1080 | 320 | 85 | 2.6 | Hot flushes, headache, nausea | 14 | 10 | 3 | Discontinue |
8 | F | 52 | 255 | 5.7 | 3.3 | 845 | 160 | 191 | 1.3 | Erythema | 30 | 8 | 0 | Discontinue |
9 | F | 31 | 29 | 4.8 | 0.1 | 17 | 1280 | 98 | 0.5 | Nausea | 44 | 8 | 0 | Discontinue |
10 | F | 60 | 210 | 4.2 | 1.8 | 250 | 80 | 359 | 0.6 | Urticaria | 14 | 8 | 0 | Discontinue |
11 | F | 52 | 168 | 3.5 | 0.3 | 15 | 1280 | 121 | 0.3 | Urticaria | 2 | 6 | 0 | Discontinue |
12 | F | 57 | 360 | 6.6 | 6.4 | 98 | 1280 | 360 | 1.5 | Erythema | 14 | 6 | 4 | Discontinue |
13 | F | 33 | 21 | 6.6 | 5.2 | 122 | 80 | 612 | 1.1 | Erythema | 14 | 10 | 4 | Continue |
14 | F | 37 | 9 | 7.5 | 5.6 | <5 | 0 | 280 | 1.9 | Fever | 14 | 6 | 10 | Discontinue |
15 | F | 37 | 60 | 4.3 | 1.4 | 446 | 80 | ND | 0.8 | Erythema | 30 | 8 | 0 | Continue |
16 | F | 63 | 4 | 7.4 | 11.0 | 1060 | 80 | 412 | 2.5 | Nausea, vomiting | 14 | 8 | 7.5 | Discontinue |
17 | F | 64 | 134 | 6.0 | 0.8 | <5 | 1280 | 253 | 1.9 | Erythema | 22 | 6 | 0 | Discontinue |
ANA, antinuclear antibody; CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; HAQ-DI, Health Assessment Questionnaire-Disease Index; MMP, matrix metalloproteinase; MTX, methotrexate; ND, not done; PRED, prednisolone; RF, rheumatoid factor.